Inactive Instrument

Highlights Inovio Pharmaceuticals Inc Nyse

Equities

US45773H1023

End-of-day quote Nyse Other stock markets
- ^USD	-

Apr. 16	Powell Comments, Middle East Tensions in Focus as US Equity Futures Gain Pre-Bell	MT
Apr. 16	Inovio Pharmaceuticals Shares Slump Pre-Bell After Pricing of $36 Million Offering of Common Stock, Warrants	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Premarket Decliners	Apr. 16	MT
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Reverse Split: 1 of 12	Jan. 24	FA
Inovio Pharmaceuticals, Coherus BioSciences to Collaborate on Potential Throat Cancer Treatment	Jan. 04	MT
INOVIO and Coherus Announces Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI?? (toripalimab-Ttzi)	Jan. 04	CI
Inovio Pharmaceuticals Plans BLA Submission for INO-3107 for Recurrent Respiratory Papillomatosis Treatment	Jan. 03	MT
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program	Jan. 03	CI
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Inovio Pharmaceuticals, Inc. Receives FDA Feedback That Data from Completed Phase 1/2 Trial of INO-3107	23-10-10	CI
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
INOVIO Presents New Data from A Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis	23-05-08	CI
Inovio Pharma Says EMA Panel Backed Approval of Orphan Designation for Respiratory Disease Drug Candidate	23-04-26	MT
European Committee for Orphan Medicinal Products Provides Positive Opinion on Inovio's Application for Orphan Drug Designation for INO-3107	23-04-26	CI
Inovio Pharmaceuticals, Inc. Announces Data from Phase 1b Trial with INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) Presented at ECCMID 2023	23-04-17	CI
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-01	CI
Inovio Pharmaceuticals, Inc. Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis	23-02-16	CI
Inovio Reports Positive Phase 1B Results for INO-4201 as an Ebola Booster for rVSV-Zebov (Ervebo®)	23-02-02	CI
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800	22-10-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Inovio Pharmaceuticals Inc Nyse

Equities

US45773H1023

Highlights

Filters